Literature DB >> 8730982

Lack of effect of chloroquine on the debrisoquine (CYP2D6 and S-mephenytoin (CYP2C19) hydroxylation phenotypes.

C M Masimirembwa1, L L Gustafsson, M L Dahl, Y A Abdi, J A Hasler.   

Abstract

The effects of chloroquine (CHQ) on debrisoquine hydroxylase (CYP2D6) and S-mephenytoin hydroxylase (CYP2C19) were assessed in 11 black Zimbabwean and 12 white Swedish healthy volunteers. The activity of CYP2D6 was measured as the urinary debrisoquine to 4-hydroxydebrisoquine metabolic ratio and that of CYP2C19 as the urinary S- to R-mephenytoin enantiomer ratio (S/R). There were no statistically significant differences in either metabolic ratio as a result of prophylactic or loading doses of CHQ. This indicates that CHQ does not inhibit CYP2D6 or CYP2C19 in vivo and is unlikely to compromise the metabolism of substrates for these two enzymes. It is, therefore, also unlikely that residual CHQ in populations under study will interfere with phenotyping of either CYP2D6 or CYP2C19.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8730982      PMCID: PMC2042586          DOI: 10.1046/j.1365-2125.1996.30713.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

Review 1.  Pharmacokinetic interactions of antimalarial agents.

Authors:  P T Giao; P J de Vries
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements.

Authors:  J Ducharme; R Farinotti
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

3.  Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians.

Authors:  O O Simooya; G Sijumbil; M S Lennard; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  1998-03       Impact factor: 4.335

4.  Influence of hydroxychloroquine on the bioavailability of oral metoprolol.

Authors:  M Somer; J Kallio; U Pesonen; K Pyykkö; R Huupponen; M Scheinin
Journal:  Br J Clin Pharmacol       Date:  2000-06       Impact factor: 4.335

5.  Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent.

Authors:  H G Xie; R B Kim; C M Stein; G R Wilkinson; A J Wood
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

6.  Chloroquine modulation of specific metabolizing enzymes activities: investigation with selective five drug cocktail.

Authors:  A Adedoyin; R F Frye; K Mauro; R A Branch
Journal:  Br J Clin Pharmacol       Date:  1998-09       Impact factor: 4.335

Review 7.  Metabolism and Interactions of Chloroquine and Hydroxychloroquine with Human Cytochrome P450 Enzymes and Drug Transporters.

Authors:  Slobodan Rendic; Frederick Peter Guengerich
Journal:  Curr Drug Metab       Date:  2020       Impact factor: 3.731

8.  Effects of Khat (Catha edulis) use on catalytic activities of major drug-metabolizing cytochrome P450 enzymes and implication of pharmacogenetic variations.

Authors:  Worku Bedada; Fernando de Andrés; Ephrem Engidawork; Jemal Hussein; Adrián LLerena; Eleni Aklillu
Journal:  Sci Rep       Date:  2018-08-24       Impact factor: 4.379

Review 9.  Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection.

Authors:  Melanie R Nicol; Abhay Joshi; Matthew L Rizk; Philip E Sabato; Radojka M Savic; David Wesche; Jenny H Zheng; Jack Cook
Journal:  Clin Pharmacol Ther       Date:  2020-09-01       Impact factor: 6.903

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.